Help | RSS Feed



Jazz Pharmaceuticals, Inc. (NASD:JAZZ) Seasonal Chart

Seasonal Chart Analysis

Analysis of the Jazz Pharmaceuticals, Inc. (NASD:JAZZ) seasonal charts above shows that a Buy Date of November 3 and a Sell Date of January 22 has resulted in a geometric average return of 8.95% above the benchmark rate of the S&P 500 Total Return Index over the past 13 years. This seasonal timeframe has shown positive results compared to the benchmark in 11 of those periods. This is a very good rate of success, but the return underperforms the relative buy-and-hold performance of the stock over the past 13 years by an average of 0.84% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and indications in neuroscience and hematology-oncology. Jazz’s product portfolio includes its lead drug, Xyrem, for narcolepsy, Sunosi for improving wakefulness in patients with excessive daytime sleepiness, Defitelio for severe veno-occlusive disease after stem cell transplant, Vyxeos for acute myeloid leukemia, and Zepzelca for small cell lung cancer.

To download JAZZ seasonal chart data, please log in or Subscribe.

 

Stocks mentioned in this post:

    Search Seasonal Charts by Symbol, Company, or Term

   Symbols by Letter: A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z